Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

China Lumena, Foxconn, ICBC, Shenhua: Hong Kong Equities Preview

The following companies may have significant price changes in Hong Kong trading. Stock symbols are in parentheses. Share prices are as of the last close.

The Hang Seng Index fell 0.1 percent to 21,987.29. The Hang Seng China Enterprises Index, which tracks so-called H shares of Chinese companies, declined 0.5 percent to 12,322.25.

China Lumena New Materials Corp. (67 HK): The mineral producer said Chairman Suolang Duoji’s effective stake fell to 33.2 percent from 63.3 percent. The stock gained 4 percent to HK$2.60.

China Shenhua Energy Co. (1088 HK): China’s largest coal miner by market value said its commercial coal production in June rose 40 percent from a year earlier to 24.8 million tons. The stock rose 0.5 percent to HK$38.80.

Foxconn International Holdings Ltd. (2038 HK): The phone unit of the world’s biggest contract maker of electronics said it expects first-half net loss to narrow “significantly” from a year earlier on smaller impairment charges and wider gross profit margins. The stock gained 2.8 percent to HK$3.62.

Guotai Junan International Holdings Ltd. (1788 HK): The brokerage expects first-half profit to increase “significantly” from a year earlier from growth of margin and other financing business. The stock declined 1 percent to HK$2.91.

Industrial & Commercial Bank of China Ltd. (1398 HK): China’s biggest bank by market value expects full-year net income to rise by 21 percent to more than 200 billion yuan ($31 billion), Shanghai Daily reported. An unidentified spokesman for the company said the report was “misinformation,” the Hong Kong Economic Journal reported today. The stock was unchanged at HK$5.71.

Shanghai Pharmaceuticals Holding Co. (2607 HK): T. Rowe Price Associates, Inc., a U.S.-based investment management firm, bought 2.3 million H-shares of the Chinese pharmaceuticals maker at an average price of HK$18.898 each on July 19, according to a disclosure statement to the Hong Kong stock exchange. The stock declined 0.3 percent to HK$18.96.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.